Table 1 Clinical characteristics, treatment, and outcome of six patients with HHT treated with topical propranolol for epistaxis
Pt. no. | Demographics & HHT features | Topical propranolol treatment -- duration and outcome measures | |||||
|---|---|---|---|---|---|---|---|
Age/ gender (M/F) | HHT mutation | Other HHT features | Treatment duration (wks) | ESS before/ after 12 wks treatment | Hb (gr%) before/after 12 wks treatment | PC before treatment/after 12 wks/after 24 wks | |
1 | 72/M | Endoglin | PAVMs, GI bleed | 48 | 7.3/1.5 | 7.4/10.9 | 10/3/0 |
2 | 55/F | Endoglin | HAVMs, GI bleed | 12 | 4.4/1.9 | 12/12 | – |
3 | 68/F | ACVRL-1 | PAVMs, HAVMs | 38 | 10/5.9 | 5.4/9.9 | 9/6/0 |
4 | 41/M | ACVRL-1 | PAVMs | 34 | 4.4/2.5 | 12.5/14 | – |
5 | 37/F | ACVRL-1 | None | 26 | 6.2/4.2 | 6.1/10 | – |
6 | 76/F | Not done | HAVMs | 26 | 6.4/4.9 | 7.1/9.1 | 8/6/2 |
p | 0.028a | 0.043a | 0.109a (12 weeks) 0.109a (24 weeks) | ||||